Polymorphic transitions of cimetidine during manufacture of solid dosage forms

International Journal of Pharmaceutics

Volumn 140, Issue 2, 1996, Pages 195-206

  Bauer Brandl, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cimetidine; Differential scanning calorimetry; Grinding; Polymorph; Tablet; X ray diffraction

Indexed keywords

CIMETIDINE;

ARTICLE; CHEMICAL MODIFICATION; COMPRESSION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; INFRARED SPECTROSCOPY; MICROSCOPY; MOLECULAR STABILITY; PARTICLE SIZE; PRIORITY JOURNAL; TABLET MANUFACTURE; X RAY DIFFRACTION;

EID: 0030606872     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04587-5     Document Type: Article

References (41)

1. Bauer, A., Braun, G. and Müller, F., Measurement of rocksalt crystal orientation upon tableting. Acta Pharm. Technol., 36 (1990) 85-90.
2. Bavin, P.M.G., Post, A. and Zarembo, E. in: Analytical Profiles of Drug Substances and Excipients (K. Florey. ed.). Academic Press, Orlando. Florida. 1984, Vol. 13. pp. 127-182; Vol. 17. p. 797.
3. Bavin, P.M.G., Post, A. and Zarembo, E. in: Analytical Profiles of Drug Substances and Excipients (K. Florey. ed.). Academic Press, Orlando. Florida. 1984, Vol. 13. pp. 127-182; Vol. 17. p. 797.
4. 2-Rezeptor-Antagonist. Patent GB 39065-76 (1976).
5. Borka, L., Review on crystal polymorphism of substances in the European Pharmacopoeia. Pharm. Acta Helv., 66 (1991) 16-22.
6. Burger, A., Zur Interpretation von Polymorphie-Untersuchungen. Acta Pharm. Technol., 28 (1982) 1-20.
7. 2-receptor antagonist, in healthy man. Br. J. Clin. Pharmacol., 2 (1975) 481-486.
8. Burns, K., Prout, K. and Durant G.J., Crystal and Molecular structure of N-Nitrosocimetidine nitrate. J. Chem. Soc. Perkin Trans., 2 (1983) 1239-1242.
9. Chan, H. and Doelker, E., Polymorphic transformations of some drugs under compression. Drug Dev. Ind. Pharm., 11 (1985) 315-322.
10. Greenaway, F.T., Brown, L.M., Dabrowiak, J.C., Thompson, M.R. and Day, V.W., Copper (II) complexes of the antiulcer drug cimetidine. J. Am. Chem. Soc., 102 (1980) 7782-7784.
11. Haleblian, J. and Mc Crone, W., Pharmaceutical Applications of Polymorphism. J. Pharm. Sci., 58 (1969) 911-929.
12. 2 Rezeptor Antagonist. Chem. Ber., 111 (1978) 3222-3232.
13. Harsanyi, K., Domany, G., Fuchs, O., Toldy, L., Fekete, G., Hegedüs, B., Morasz, F., Rado, A., Lang, T., Lazar, A., Csongor, E., Balogh, T., Borvendeg, J., Reiter, J., Somogyi, T. and Bidlo, M., Cimetidinmonohydrat und Verfahren zur Herstellung desselben, Patent BE 593670 (1981).
14. Hegedüs, B. and Görög, S., The polymorphism of cimetidine. J. Pharm. Biomed. Anal., 3 (1985) 303-313.
15. Hüttenrauch, R., Molekulargalenik als Grundlage moderner Arzneiformung. Acta Pharm. Technol. Suppl., 6 (1978) 55-127.
16. Kajfez, F., Lisini, A., Toso, R., Bein, B. and Sunjic, V., Study of physico-chemical properties of (cimetidine) and it S-oxid, Acta Pharmacol. Jugoslav., 27 (1977) 199-207.
17. Kala, H., Traue, J., Haak, U., Moldenhauer, H., Kedvessy, G. and Selmeczi, B., Zur Zeitabhängigkeit der Modifikationsumwandlung des Sulfanilamids bei der Tablettenkompression. Pharmazie, 37 (1982) 674-675.
18. Kamiya, H., Morimoto, K. and Morisaka, K., Dissolution behavior and bioavailability of eimetidine-hydrochloride. Int. J. Pharm., 26 (1985) 197-200.
19. Kaneniwa, N. and Otsuka, M., Effect of grinding on the transformation of polymorphs of chloramphenicol palmitate. Chem. Pharm. Bull., 33 (1985) 1660-1668.
20. Kojic-Prodic, B., Ruzic-Toros, Z., Bresciani-Pahor, N. and Randaccio, L., 2-Cyano-1-methyl-3-(2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl/guanidine Monohydrate. Acta Crystallogr., B36 (1980) 1223-1225.
21. Kokubo, H., Morimoto, K., Ishida, T., Inoue, M. and Morisaka, K., Bioavailability and inhibitory effect for stress ulcer of cimetidine polymorphs in rats. Int. J. Pharm., 35 (1987) 181-183.
22. Kopp, S., Beyer, C., Graf, E., Kubel, F. and Doelker, E., Methodology for a better evaluation of the relation between mechanical strength of solids and polymorphic form. J. Pharm. Pharmacol., 41 (1989) 79-82.
23. Kreidl, J., Farkas, M., Harsanyi, K., Benke, B., Rado, A., Domany, G., Hegedüs. B., Csongor, E., Deutsch, I. and Pethö, H., Cimetidin Z und Verfahren zur Herstellung desselben und von Cimetidin A sowie das erstere enthaltende Arzneimittel. Patent BE 894464 (1981).
24. Kuhnert-Brandstätter, M. and Burger, A., Untersuchungen zum Auflösungsverhalten polymorpher, pseudopolymorpher und amorpher Phasen von Arzneimittein. Pharm. Ind., 34 (1972) 187-190.
25. Otsuka, M., Otasuka, K. and Kaneniwa, N., Relation between polymorphic transformation pathway during grinding and the physicochemical properties of bulk powders for pharmaceutical preparations. Drug Dev. Ind. Pharm., 20 (1994) 1649-1660.
26. Pharmazeutische Bestimmungsliste. 1994 95. IMP Neu-Isenburg 1994. ISSN 0171-6255.
27. 6S. Acta Crystallogr., C40 (1984) 676-679.
28. Pirttimäki, J., Laine, E., Ketolainen, J. and Paronen, P., Effect of grinding and compression on crystal structure of anhydrous caffeine. Int. J. Pharm., 95 (1993) 93-99.
29. Pounder, R.E., Williams, J.G., Russelll, R.C.G., Milton-Thompson. G.J. and Misiewicz. J.J., Inhibition of food-stimulated gastric acid secretion by cimetidine. Gut. 17 (1976) 161-168.
30. Prodic-Kojic, B., Kajfes, F., Belin, B., Toso, R. and Sunjic, V., Study of crystalline forms of N-Cyano-N′-Methyl-N″-/2/[(4-methyl-1 H-imidazol-5-yl )methyl]thio/ethyl/! guanidine (Cimetidine). Gazz. Chim. Ital., 109 (1979) 535 539.
31. Röscheisen, G., Optimierung von Schmiermitteln für Brausetabletten. Ph.D. Thesis. University of Tübingen. Germany, 1994.
32. Schepky, G., Ein Hygrostal mit einfacher und störungsarmer Probenauswaage. Acta Pharm. Technol., 28 (1982) 87-88.
33. Shibata, M., Kagawa, M., Morisaka, K., Ishida, T. and Inoue. M., Structure of cimetidine monohydrochloride-monohydrate. Acta Crystallogr., C39 (1983b) 1255-1257.
34. Shibata, M., Kokubo, H., Morimoto, K., Morisaka, K., Ishida, T. and Inoue, M., X-ray structural studies and physicochemical properties of cimetidine polymorphism. J. Pharm. Sci., 72 (12) (1983a) 1436-1442.
35. Sudo, S., Sato, K. and Harano, Y., Solubilities and crystallization behaviour of cimetidine polymorphic forms A and B. J. Chem. Eng. Jpn., 24 (1991a) 237-242.
36. Sudo, S., Sato, K. and Harano, Y., Growth and solvent-mediated phase transition of polymorphic forms A and B. J. Chem. Eng. Jpn.. 24 (1991b) 628-632.
37. Sudo, S., Sato, K., Harano, Y. and Ogo, Y., Solid Phase Transition of Cimetidine Polymorphic Forms A and B. Mem. Fac. Eng., Osaka City University, Vol. 31, 1990, pp. 61-67.
38. Trautmann, H., Stofftransport durch pharmazeutisch relevante Membranen. Ph.D. Thesis. University of Freiburg, Germany. 1990.
39. Tudor, A.M., Davies. M.C., Melia, C.D., Lee, D.C., Mitchell, R.C., Hendra, P.J. and Church, S.J., The application of near-infrared Fourier transform Raman spectroscopy to the analysis of polymorphic forms of cimetidine. Spectrochim. Acta. 47A (1991) 1389-1393.
40. Verma, A.R. and Krishna, P., Polymorphism and Polytypism in Crystals, Wiley, New York, 1966.
41. York, P., Crystal engineering and particle design for the powder compaction process. Drug Dev. Ind. Pharm., 18 (1992) 677-721.